Intrahepatic cholangiocarcinoma

Kimberly M Brown; Abhishek D Parmar; David A Geller

doi:10.1016/j.soc.2013.10.004

Intrahepatic cholangiocarcinoma

Surg Oncol Clin N Am. 2014 Apr;23(2):231-46. doi: 10.1016/j.soc.2013.10.004.

Authors

Kimberly M Brown¹, Abhishek D Parmar², David A Geller³

Affiliations

¹ Department of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0541, USA. Electronic address: km3brown@utmb.edu.
² Department of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0541, USA; Department of Surgery, University of California San Francisco-East Bay, 1411 East 31st Street, Oakland, CA 94602, USA.
³ Liver Cancer Center, University of Pittsburgh School of Medicine, 3459 Fifth Avenue, Pittsburgh, PA 15213-2582, USA. Electronic address: gellerda@upmc.edu.

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43 months.

Keywords: Bile duct neoplasms; Cholangiocarcinoma; Intrahepatic bile duct cancer; Intrahepatic cholangiocarcinoma; Peripheral cholangiocarcinoma.

Intrahepatic cholangiocarcinoma

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding